"Archival cytology sample with adequate tumor cells can yield genetic information compared to the primary tumors. If tumor tissue samples are unavailable, we can use archival cytology samples to search for actionable driver mutations."
Cancer Med. 2020 Apr 29.
"Our findings suggest that combination treatment with ATRA prevents gefitinib-induced enrichment of
ALDH1A1bright/CD44high CSCs and enhances gefitinib-induced growth inhibition of NSCLC/ADC cells."
BMC Cancer. 2020 Apr 15;20(1):315.
"Discarded supernatants provided an adequate amount of cell-free DNA for EGFR detection, and this means
that the pellets can be reserved for additional morphological and molecular analyses or to avoid repeat biopsies. Analyzing the EGFR status in cell supernatants and pellets might improve detection sensitivity and confer benefits to patients."
Cancer Cytopathol. 2020 Apr 14.
"The data demonstrated that the performance of individual Chinese laboratories for EML4-ALK testing continuously improved over time by participating PT schemes,
regardless of their method. However, care must be taken in standardized operations and validations."
J Mol Diagn.2020 Jul;22(7):876-884.
our results indicated that wild-type and mutant IDH1 opposingly controlled the Pdpn expression in glioma by regulating its promoter methylation, which provides a basis for understanding the relationship between wild-type and mutant IDH1 in epigenetic regulation and tumorigenesis.
Transl Oncol. 2020 Apr;13(4):100758.
Pin1 inhibition with clinical widely used ATRA acts as an effective HR disrupter that sensitizes BRCA1-proficient tumors to PARP inhibition.
Cancer Res. 2020 Mar 19. pii: canres.2739.2019.